|Awarded On||August 20, 2014|
|Title||Novel Targets for Acute Myeloid Leukemia Treatment|
|Award Mechanism||Individual Investigator|
|Institution/Organization||The University of Texas Southwestern Medical Center|
|Principal Investigator/Program Director||Chengcheng Zhang|
Acute myeloid leukemia (AML) is the most common acute leukemia affecting adults. Despite continuous treatment, the majority of the patients relapse within 5 years. Leukemia stem cells (LSCs) may be responsible for the relapse of disease following a remission brought about by conventional chemotherapy, and new molecular targets and therapeutic approaches need to be identified to effectively inhibit LSC activity. Our research has indicated that the inhibitory receptor LAIR1 supports the self-renewal and survival of human leukemia cells. We found that LAIR1 is highly expressed on cells from AML patients and that LAIR1+ primary human AML cells are enriched for AML stem cell (AML-SC) activity. In...